Want to see OMDA full AI Analyst Report?
EarningsQ2 2026 Earnings Report
OMDA Q2 2026 EPS Results
Actual EPS$0.18
Consensus EPS$0.06
Beat/MissBeat by +$0.12
One Year Ago EPS-$0.24
OMDA Q2 2026 Revenue Results
Actual Revenue$87.83M
Expected Revenue$80.04M
Beat/MissBeat by +$7.79M
YoY Revenue Growth+43.12%
Earnings Announcement Details
QuarterQ2 2026
Date08/06/2026
TimeAfter Close
Conference CallThursday, August 6, 2026
OMDA Upcoming Earnings
Omada Health, Inc.'s next earnings date is estimated for November 5, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
OMDA Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
The call conveyed strong operational and financial momentum: record revenue, significant margin expansion, profitability, rapid membership growth, AI-driven efficiency gains, product launches (GLP-1 prescribing, cholesterol), and raised full-year guidance. Noted risks include seasonal moderation in H2, employer uncertainty around GLP-1 coverage, early-stage channels that require execution, and some near-term margin moderation as investments annualize. Overall the positives are broad and material and management provided clear plans to scale and convert pipeline.Company Guidance
Record Quarter: Revenue and Profitability
Q2 revenue of $88 million, up 43% year-over-year and 13% sequentially; GAAP net income of $5 million vs a GAAP net loss of ~$5 million in Q2 last year (≈$11 million YoY improvement); adjusted EBITDA of $11 million (record), improving ~$11 million YoY.
Strong Membership Growth and Reach
Total members ~1.1 million at quarter end, up 45% year-over-year; company has served more than 2 million lifetime members and reported >25 million estimated eligible covered lives (as of Dec 2025).
Material Gross Margin Expansion
GAAP gross margin expanded to 73% (up ~700 basis points YoY); non-GAAP gross margin 74% (up ~600 basis points YoY). Management reiterated a path to exceed the prior long-term 70% gross margin target.
Improved Unit Economics and Efficiency
Trailing 12-month revenue per member of $284 vs $279 prior year (modestly higher); cost to serve declined >10% YoY (cost of revenue per member on a TTM basis); members remain active ~10% longer YoY, increasing billable months and LTV.
Operating Leverage and Expense Discipline
Non-GAAP operating expenses fell from 68% of revenue a year ago to 62% this quarter (≈6 percentage point improvement); company delivered ~41% incremental adjusted EBITDA margin this quarter.
Balance Sheet Strength
Cash and cash equivalents of approximately $222 million at quarter end and no debt.
Raised Full-Year Guidance
Raised 2026 revenue guidance to $334M-$340M (from $322M-$330M) — midpoint implies ~30% growth vs 2025; raised adjusted EBITDA guidance to $21M-$27M (from $14M-$20M) — midpoint implies an ~ $18M improvement vs 2025 (~4x).
Product and Channel Momentum
Progress across GLP-1 care track, new prescribing program, and standalone cholesterol product with early customer traction; deeper partnerships with major PBMs and expansion with HCSC adding ~1.5 million covered lives (launching 2027).
AI Driving Efficiencies
Management cites AI and machine learning adoption across care and operations as a driver of lower care delivery cost, higher coach capacity, better enrollment targeting, and overall operating leverage.
Improved Enrollment Effectiveness
Primary email enrollment channel conversion improved ~20% year-over-year, indicating better targeting, personalization, and messaging.
OMDA Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed